



# Structural study of P-glycoprotein-mediated transport of A $\beta$ across the blood-brain barrier in Alzheimer's disease

Rohan Mehrotra • Steven Rees • Geoffrey Chang

Skaggs School of Pharmacology and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California


## INTRODUCTION

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects over 35 million people and leads to a severe loss of mental function.<sup>1</sup>

The cause of AD is unclear. However, research has revealed that the disease is characterized by the accumulation of amyloid beta (A $\beta$ ), a protein that can form toxic oligomers.<sup>1</sup> While the cause of the accumulation of A $\beta$  is not known, the "amyloid hypothesis" suggests it is due to an imbalance between A $\beta$  production and clearance.<sup>2</sup> Further evidence suggests that transport across the blood-brain barrier may have an important role in the observed reduced clearance of A $\beta$ .<sup>3</sup>

Recently, it has been suggested that P-glycoprotein (Pgp) is involved in the clearance of A $\beta$  from the brain.<sup>4</sup> Pgp is a membrane protein that has a protective role in the body, as it is expressed at barriers like the intestine, and also effluxes many xenobiotics.<sup>4</sup> Pgp is highly expressed at the luminal (blood) side of the blood-brain barrier.<sup>5</sup> There, it extrudes substances from the brain to the blood, including toxins.<sup>5</sup> In this way, Pgp plays an important role in protecting the brain.


Studies have provided evidence that Pgp may clear A $\beta$  from the brain to the blood.<sup>4</sup> One study showed lower A $\beta$  accumulation with higher Pgp expression.<sup>6</sup> Available data suggests that Pgp is involved in the clearance of A $\beta$ , and thus may be a significant factor in AD.



## METHODS

### GROWTH

Express mouse Pgp in *P. pastoris*



Grow *P. pastoris*




Induce Pgp expression with methanol

Harvesting


### PURIFICATION

Disruption, Centrifugation



Detergent solubilization

Ni affinity chromatography



Size exclusion chromatography

Protein concentration


### CRYSTALLIZATION

Pgp incubated with A $\beta$



Reductive methylation

Set crystallization trays with mother liquor and protein



## RESULTS




Figure A: UV absorbance of material running through Ni affinity chromatography.




Figure B: Results from SDS-PAGE of protein after Ni purification.




Figure C: UV absorbance of material running through size exclusion chromatography.



Figure D: Crystals of Pgp grown after incubation with A $\beta$ .

The pictures above demonstrate results showing that we were able to successfully purify Pgp and form crystals of Pgp in trials where Pgp was co-treated with A $\beta$ . The crystals will be tested for presence of A $\beta$  and, if positive, used for structural elucidation.

## CONCLUSIONS

We were able to successfully express mouse P-glycoprotein in yeast and purify the protein using various techniques. We also obtained crystals in conditions where Pgp was incubated with A $\beta$ . We will verify if the crystals that appeared in these conditions are Pgp-A $\beta$  co-crystals. If A $\beta$  is present, we will obtain x-ray diffraction data towards generating a structural model of the A $\beta$ -Pgp interaction. The structure would show how Pgp interacts with A $\beta$  at the atomic level. Furthermore, this structure would show if any conformational changes occur, and with which residues in the drug-binding pocket A $\beta$  interacts. The ultimate goal is using the co-crystal structure in order to further characterize Pgp-mediated transport of A $\beta$ , which is a promising target in Alzheimer's disease.

## REFERENCES

1. Querfurth, Henry W., et al. "Alzheimer's Disease." *N Engl J Med* 362.4 (2010): 329-44.
2. Hardy, John, et. al. "The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics." *Science* 297.5580 (2002): 353-56.
3. Deane, Rashid, et. al. "Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimer's Disease." *Current Alzheimer Research* 4.2 (2007): 191-97.
4. Vogelgesang, Silke, et. al. "The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of  $\beta$ -Amyloid Across the Blood-Brain Barrier." *Current Pharmaceutical Design* 17.26 (2011): 2778-786.
5. De Lange, Elizaeth C. "Potential Role of ABC Transporters as a Detoxification System at the Blood-CSF Barrier." *Advanced Drug Delivery Reviews* 56.12 (2004): 1793-809.
6. Vogelgesang, Silke. "Deposition of Alzheimer's Beta-amyloid Is Inversely Correlated with P-glycoprotein Expression in the Brains of Elderly Non-demented Humans." *Pharmacogenetics* 12.7 (2002): 535-41.